Favorable rates of cardiovascular events with stringent cardiovascular monitoring and a lowered dose of ponatinib as second line treatment in chronic phase chronic myeloid leukemia (CML-CP) patients failing or intolerant to first-line second generati
We demonstrated that a lowered dose of 30 mg ponatinib in selected patients can be maintained without serious cardiovascular complications, provided cardiovascular risk monitoring is performed. In our patient cohort, this approach resulted in favorable response rates.
Authors
- Tobias Schwarzer (ORCID: https://orcid.org/0000-0001-7914-7774)
- Uwe Pelzer (ORCID: https://orcid.org/0000-0001-9213-2737)
- Frank Stegelmann (ORCID: https://orcid.org/0000-0003-2157-476X)
- Susanne Saußele (ORCID: https://orcid.org/0000-0003-0357-5785)
- Sebastian Stintzing (ORCID: https://orcid.org/0000-0002-3297-5801)
- Andreas Hochhaus (ORCID: https://orcid.org/0000-0003-0626-0834)
- Philipp le Coutre (ORCID: https://orcid.org/0000-0003-4532-1097)
- Lars Bullinger (ORCID: https://orcid.org/0000-0002-5890-5510)
- Ahmet Elmaağaclı
- Andreas Burchert (ORCID: https://orcid.org/0000-0002-8411-8844)
- Thomas Ernst (ORCID: https://orcid.org/0000-0002-2170-9241)
- Joachim R. Göthert (ORCID: https://orcid.org/0000-0001-8957-6732)
- Christian Jehn
Institutions
- Jena University Hospital (DE)
- University Hospital Ulm (DE)
Publication Details
- Journal
- Acta Haematologica
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1159/000545826
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77